ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1707

IL-6 Promotes IgG4-related Disease by Inducing Fibroblast-dependent Tfh Cell and B Cell Differentiation Factors

Zongfei Ji1, Rongyi Chen 2, Xiaomeng Cui 2, Lili Ma 2, Xiufang Kong 3, Lingying Ma 2, Ying Sun 2, Xiaomin Dai 2, Zhuojun Zhang 2, Huiyong Chen 2 and Lindi Jiang 2, 1Department of Rheumatology, Zhongshan hospital, Fudan University, Shanghai, China (People's Republic), 2Zhongshan hospital, Fudan University, Shanghai, China (People's Republic), 3University of Michigan & Fudan University, Ann Arbor, MI

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: IgG4 Related Disease and fibroblasts, IL-6

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Considering the unsatisfied effect of conventional therapy, to investigate the pathogenesis of IgG4-related disease (IgG4-RD) is crucial to explore novel treatment strategies.  This study aims to clarify the pathogenesis of interleukin 6 (IL-6) in IgG4-RD through the induction of fibroblast-dependent Tfh cell and B cell differentiation factors and find the new therapeutic target.

Methods:  The IL-6 expression in the serum and tissues of patients with IgG4-RD and healthy controls were detected by ELISA, immunohistochemistry, and immunofluorescence, respectively. Human aorta adventitial fibroblasts (AAFs) were cultured and stimulated with IL-6/IL-6 receptor (IL-6R). The effect of IL-6/IL-6R on AAFs was determined by CCK-8 and Luminex assays. 

Results:  The level of serum IL-6 was elevated in active IgG4-RD patients and was positively correlated with IgG4-RD reactive index (RI). The expression of IL-6 in the tissue of IgG4-RD patients was also significantly higher than that in the normal tissue. IL-6-producing fibroblasts were found to co-localize with IgG4+ plasma cells in the tissue of IgG4-related retroperitoneal fibrosis (IgG4-RF). Co-localization of α-SMA and B cell differentiation cytokines (i.e., B cell activating factor (BAFF)), α-SMA and T follicular helper (Tfh) cell differentiation cytokines (e.g., IL-7, IL-12, and IL-23) were present in the local lesions. IL-6/IL-6R significantly promoted the production of BAFF, IL-7, IL-12, and IL-23 in AAFs in a dose-dependent manner. This effect was blocked by JAK1, JAK2, STAT3, and Akt inhibitors, respectively.

Conclusion: IL-6 promotes IgG4-RD by inducing fibroblast-dependent Tfh and B cell differentiation factors via the JAK2/STAT3, JAK1/STAT3, and JAK2/Akt pathways. Thus, IL-6 and JAK1/2 inhibitors may be therapeutic targets for IgG4-RD.

IL-6 promotes IgG4-related disease by promoting the production of B cell differentiation cytokine -BAFF-, and Tfh cell differentiation cytokines -IL-7, IL-12, and IL-23- in fibroblast.

The level of serum IL-6 was elevated in active IgG4-RD patients. The expression of IL-6 in the tissue of IgG4-RD patients was also significantly higher than that in the normal tissue. *p < 0.05; **p < 0.01

The secretion of cytokines -IL-7, BAFF, IL-12 p70, and IL-23- in the supernatant following stimulation with IL-6/IL-6R -50 ng/mL- with or without different inhibitors. **p < 0.01 versus control group; #p < 0.05 versus IL-6/IL-6R group.


Disclosure: Z. Ji, None; R. Chen, None; X. Cui, None; L. Ma, None; X. Kong, None; L. Ma, None; Y. Sun, None; X. Dai, None; Z. Zhang, None; H. Chen, None; L. Jiang, None.

To cite this abstract in AMA style:

Ji Z, Chen R, Cui X, Ma L, Kong X, Ma L, Sun Y, Dai X, Zhang Z, Chen H, Jiang L. IL-6 Promotes IgG4-related Disease by Inducing Fibroblast-dependent Tfh Cell and B Cell Differentiation Factors [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/il-6-promotes-igg4-related-disease-by-inducing-fibroblast-dependent-tfh-cell-and-b-cell-differentiation-factors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-6-promotes-igg4-related-disease-by-inducing-fibroblast-dependent-tfh-cell-and-b-cell-differentiation-factors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology